<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30126">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01938417</url>
  </required_header>
  <id_info>
    <org_study_id>Tobramycin cast</org_study_id>
    <nct_id>NCT01938417</nct_id>
  </id_info>
  <brief_title>Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to assess the systemic absorption and disposition of tobramycin in patients
      treated with a tobramycin-laden bone graft substitute (Osteoset® T).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Measurement of systemic tobramycin concentration</measure>
    <time_frame>within 10 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Develop a population pharmacokinetic model for tobramycin in patients treated with an active calcium sulfate bone substitute and to predict tobramycin systemic exposure under various dose and renal function levels.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Orthopedic Operations</condition>
  <arm_group>
    <arm_group_label>adult patients treated with Osteoset® T (tobramycin sulfate)</arm_group_label>
    <description>10 g or 20 g of Osteoset® T</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tobramycin</intervention_name>
    <arm_group_label>adult patients treated with Osteoset® T (tobramycin sulfate)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients treated with Osteoset® T in our orthopedic surgery department
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt; or =18 years old) patients

          -  Treatment with Osteoset® T

        Exclusion Criteria:

          -  Intravenous tobramycin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 10, 2013</lastchanged_date>
  <firstreceived_date>September 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>Francoise Livio, MD</investigator_full_name>
    <investigator_title>Médecin associé</investigator_title>
  </responsible_party>
  <keyword>tobramycin</keyword>
  <keyword>bone graft substitute</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>renal failure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
